Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.

Ahmed S, Martin Garcia-Sancho A, Reguera-Ortega JL, Cartron G, Rapoport AP, Izutsu K, Ghesquieres H, Goto H, Palomba ML, Abramson JS, Borchmann P, Jaeger U, Kamdar M, Dreyling M, Subklewe M, Dahiya S, Nastoupil LJ, Bar M, Strocchia M, Raggi M, Moro Bueno L, Papuga J, Colicino S, Morschhauser F

Open source

DOI: 10.1182/blood.2026034327
Published: 2026 Jul 1
Container: Blood
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/blood.2026034327,
  title = {Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.},
  author = {Ahmed S and Martin Garcia-Sancho A and Reguera-Ortega JL and Cartron G and Rapoport AP and Izutsu K and Ghesquieres H and Goto H and Palomba ML and Abramson JS and Borchmann P and Jaeger U and Kamdar M and Dreyling M and Subklewe M and Dahiya S and Nastoupil LJ and Bar M and Strocchia M and Raggi M and Moro Bueno L and Papuga J and Colicino S and Morschhauser F},
  year = {2026},
  journal = {Blood},
  doi = {10.1182/blood.2026034327},
  url = {https://doi.org/10.1182/blood.2026034327}
}

RIS

TY  - JOUR
TI  - Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.
AU  - Ahmed S
AU  - Martin Garcia-Sancho A
AU  - Reguera-Ortega JL
AU  - Cartron G
AU  - Rapoport AP
AU  - Izutsu K
AU  - Ghesquieres H
AU  - Goto H
AU  - Palomba ML
AU  - Abramson JS
AU  - Borchmann P
AU  - Jaeger U
AU  - Kamdar M
AU  - Dreyling M
AU  - Subklewe M
AU  - Dahiya S
AU  - Nastoupil LJ
AU  - Bar M
AU  - Strocchia M
AU  - Raggi M
AU  - Moro Bueno L
AU  - Papuga J
AU  - Colicino S
AU  - Morschhauser F
PY  - 2026
JO  - Blood
DO  - 10.1182/blood.2026034327
UR  - https://doi.org/10.1182/blood.2026034327
ER  -

APA

S, A., A, M. G., JL, R., G, C., AP, R., K, I., H, G., H, G., ML, P., JS, A., P, B., U, J., M, K., M, D., M, S., S, D., LJ, N., M, B., M, S., M, R., L, M. B., J, P., S, C., & F, M. (2026). Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.. Blood. https://doi.org/10.1182/blood.2026034327

Source records

pubmed · retrieved 2026-09-26T01:46:39.138Z